Enzytech Inc. announced Tuesday that it will develop deliverysystems for Centocor Inc.'s monoclonal antibody productsunder an agreement that includes a $2.5 million investment inthe company by Centocor.
The companies will collaborate to develop ways to delivermonoclonal pharmaceuticals and to control their duration ofaction inside the body.
Protein products break down in the gastrointestinal tract andcurrently must be delivered by injection.
Enzytech has two proprietary technologies. OraLease is an oraldelivery system that the company said may be capable ofconverting injectable products into tablet or capsule form.ProLease is an injection technology that uses a sustainedrelease system to reduce the number of required injections.
The drug-delivery company, based in Cambridge, Mass., alsosold 862,069 shares of its class D convertible preferred stockto Centocor. The investment gives the Malvern, Pa., companyabout 11 percent of Enzytech on a fully diluted basis.
James E. Wavle Jr., Centocor president and chief executive,also will be an Enzytech director.
(c) 1997 American Health Consultants. All rights reserved.